Aptose Biosciences is a clinical-stage biotechnology company developing personalized therapies to address unmet medical needs in oncology, with a particular focus on hematologic malignancies. Aptose is advancing new therapeutics focused on well validated and novel drug targets on the leading edge of cancer research, coupled with validated biomarkers to identify the optimal patient population for our products. The company's small molecule cancer therapeutics pipeline includes products designed for potent single agent activity and to enhance the efficacy of existing anti-cancer therapies without overlapping toxicities. Aptose Biosciences Inc. is listed on NASDAQ under the symbol APTO and on the TSX under the symbol APS.
No articles found.
Apoth?ka Blockchain: Transforms Electronic Medical Records Platforms into Secure B...
Apoth?ka Blockchain: Transforms Electronic Medi...
Pluristem Therapeutics Inc. is a clinical-stage biotherapy company using placental...
Pluristem Therapeutics Inc. is a clinical-stage...
Evogene (NASDAQ, TASE: EVGN) is a leading biotechnology company developing novel p...
Evogene (NASDAQ, TASE: EVGN) is a leading biote...
Nektar Therapeutics is a research-based development stage biopharmaceutical compan...
Nektar Therapeutics is a research-based develop...
Our strategy is to be known as âthe prostate cancer companyâ. We aspire to be ...
Our strategy is to be known as âthe prostate ...
Eiger is a late stage biopharmaceutical company focused on the development and com...
Eiger is a late stage biopharmaceutical company...
Cyclacel's founding scientist, Professor Sir David Lane, a globally recognized aut...
Cyclacel's founding scientist, Professor Sir Da...
Exicure, Inc. is a clinical stage biotechnology company developing a new class of ...
Exicure, Inc. is a clinical stage biotechnology...
Join the National Investor Network and get the latest information with your interests in mind.